Rituximab

Rituximab is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s Lymphoma (NHL) as a single agent. Also, it is indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Additionally, rituximab is indicated for the treatment of adult patients with non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy; and previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens. Rituximab, in combination with fludarabine and cyclophosphamide (FC), is indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia (CLL). In combination with methotrexate, rituximab is indicated for the treatment of adult patients with moderately-to severely-active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies. Additionally, rituximab, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA). RITUXAN (rituximab injection for intravenous use) is indicated for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy; as well as the treatment of adult patients with moderate to severe pemphigus vulgaris. These indications for RITUXAN are not included in the labels of rituximab biosimilar products (rituximab-arrx, rituximab-abbs, rituximab-pvvr). The combination product RITUXAN HYCELA (rituximab and hyaluronidase human injection, for subcutaneous use) is not indicated for the treatment of non-malignant conditions.

• Active, Moderate to Severe Rheumatoid Arthritis
• Chronic Lymphocytic Leukemia
• Diffuse Large B-Cell Lymphoma (DLBCL)
• Follicular Non-Hodgkin's Lymphoma
• Granulomatosis With Polyangiitis
• Microscopic Polyangiitis (MPA)
• Advanced Burkitt Lymphoma (BL)
• Advanced Burkitt-like lymphoma
• Advanced Diffuse Large B-Cell Lymphoma (DLBCL)
• Advanced Mature B-cell type acute leukaemia
• Moderate Pemphigus Vulgaris (PV)
• Non-progressive Low Grade Non-Hodgkin's Lymphoma (NHL)
• Refractory Low Grade Non-Hodgkin's Lymphoma (NHL)
• Refractory follicular B-cell non-Hodgkin's lymphoma
• Relapsed Low Grade Non-Hodgkin's Lymphoma (NHL)
• Relapsed follicular B-cell non-Hodgkin's lymphoma
• Severe Pemphigus Vulgaris (PV)